Survey
Quarterly Survey: Alzheimer's Disease and BIIB's Leqembi April 2024
Ticker(s): BIIB, LLYThe survey includes 20 neurological disease specialists.
How many patients with early Alzheimer’s disease (mild cognitive impairment or mild dementia stage of disease) do you manage?
Do you currently prescribe Leqembi?
What % of your [S1] Alzehimer’s patients are you prescribing Leqembi?
Describe the type(s) of Alzheimer's patients that you consider/qualify for Leqembi therapy. Please be specific.
How many of your Alzehimers patients have you started on Leqembi in the past 30 days?
How many of your Alzehimers patients do you expect to start on Leqembi in the next 30 days?
Are you more willing to prescribe Leqembi now than you were 90 days ago? Why or why not?
How satisfied with the level of support you’re receiving from Biogen/Eisai?
- Very Satisfied
- Satisfied
- Somewhat satisfied
- Neither satisfied nor dissatisfied
- Somewhat dissatisfied
- Dissatisfied
- Very dissatisfied
- Other
Has the level of support from Biogen/Eisai gotten any better or worse in the past 90 days?
- Support is better
- Support is the same
- Support is worse
Do you expect your Leqembi prescriptions to increase over the next 12 months?
- Yes
- No
(SHOW IF YES) By what % do you expect Leqembi prescriptions to increase in the next 12 months and why?
If the subcutaneous form of Leqembi receives FDA approval, how do you expect it to affect your Leqembi prescriptions?
Why is that? Please elaborate on your response above.
Assuming LLY’s donanemab receives FDA approval, what do you expect the % split between donanemab and Leqembi to be?
Why is that? Please elaborate on your response above.
What is your projected outlook for the prescribing of anti-amyloid medications over the next five years within your practice or institution?
On a scale 1-10 (where 1 is low and 10 is high) how excited are you for Leqembi?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
